Comparison of the anticoagulant effect of topical citrate and nafamostat mesylate in continuous renal replacement therapy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300078946

Enrollment

Unknown

Registered

2023-12-21

Start date

2024-01-01

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Jnjury

Interventions

Group NM (Experimental group):Nafamostat mesylate

RCA group (control group):Regional citrate

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (i) Patients in the ICU who are older than 18 years old; (ii) Patients who need CRRT due to renal insufficiency or internal environment disorder, or to protect other organs; (iii) Patients who have signed the informed consent form and voluntarily participate in this study.

Exclusion criteria

Exclusion criteria: ? History of allergy to sodium citrate and nafamostat mesylate; ? Severe hepatic impairment (Child-Pugh classification > grade C); ? Patients with difficulty in establishing vascular access; ? Pregnant patients. ? People with lactic acidosis (Arterial blood lactate level >5.0 mmol/L, anion gap >18 mmol/L, pH<7.35)

Design outcomes

Primary

Measure	Time frame
Service life (h) and quantity of each filter used within 72 hours;Bleeding after treatment with two groups of CRRT anticoagulants;	—

Secondary

Measure	Time frame
The rate of creatinine decrease in patients after a single CRRT treatment process;	—

Countries

China

Contacts

Public ContactYibing Weng

Beijing Luhe Hospital, Capital Medical University

yibingweng@ccmu.edu.cn+86 10 6954 3901

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026